HP. Daiichi Sankyo. Tata Teleservices. Three boardrooms. Three costly failures. One repeating mistake.

79% Premium HP paid over Autonomy’s market price — called ‘absurdly high’ before the ink dried

$500M Ranbaxy’s criminal fine in May 2013 — the largest ever by a generic drug company at the time

$7.3Bn What Tata paid just to settle dues and complete the exit from its own telecom arm

Introduction – When Buying a Business Means Buying Its Problems

Every acquisition starts the same way: a confident announcement, a strategic rationale, and a number that makes investors sit up. The press release talks about synergies, market leadership, and transformational potential. What it doesn’t mention is what the acquiring company actually knows – or more often, what it doesn’t. The decade between 2010 and 2020 produced some of the most expensive due diligence failures in corporate history. Not because the buyers were careless or naive – many had armies of advisors and months of preparation. But somewhere between the data room and the signing dinner, the right questions either weren’t asked, weren’t answered honestly, or the answers were buried deep enough that nobody looked. The result, in every case, was the same: the acquirer inherited a problem it thought it was buying an asset.

Three cases from this period stand out – not just for the scale of the financial fallout, but for how clearly, in hindsight, the warning signs were there. HP and Autonomy. Daiichi Sankyo and Ranbaxy. Tata Motors and Tata Teleservices. Each tells a slightly different story about how acquisitions go wrong. Together, they demonstrate what happens when financial, regulatory, and strategic risks are not independently challenged before it is too late to change course.

Case 1 – Tata Teleservices (2017-2020): When the Exit Costs More Than the Entry

The Setup

Tata Teleservices was one of India’s mid-tier telecom operators, a subsidiary of Tata Sons. By 2016, it was already a business under severe financial pressure – Tata Sons had been infusing capital to fund its losses and debt repayments for years. Then in September 2016, Reliance Jio launched its services with free voice calls and heavily subsidised data. Analysts immediately warned that the move made survival for smaller telecom players “very difficult.” Tata Teleservices was among the most exposed.

In September 2017, Tata Group announced that Bharti Airtel would acquire Tata Teleservices’ consumer mobile telephony business. The deal was structured with no upfront cash payment to Tata – an immediate signal of how little bargaining power Tata had in a market it was effectively fleeing. At the time of the announcement, analysts warned that even with the deal, the exit could cost Tata Group $4-5 billion. That estimate, as it turned out, was an undercount.

What the Exit Actually Cost

To complete the transfer of the consumer mobile business to Bharti Airtel, Tata Group paid lenders and the government approximately ₹500 billion ($7.3 billion) in settlement of dues. The consumer mobile business formally became part of Bharti Airtel on 1 July 2019. But the financial damage didn’t stop there.

Between January 2014 and December 2019, Tata Sons had infused approximately ₹46,595 crore into Tata Teleservices to fund losses, debt repayments, and capital expenditure. By FY2020, Tata Teleservices reported a net loss of ₹13,225 crore and accumulated losses of ₹48,907 crore. And then came a further hit: the Supreme Court ordered Tata Teleservices to pay approximately ₹13,823 crore in Adjusted Gross Revenue (AGR) dues to the government. Tata Sons was forced to arrange ₹10,000 crore from banks and the rest from internal accruals to meet the deadline set by the court.

“Tata Group paid lenders and the government about 500 billion rupees ($7.3 billion) to help complete the sale of its mobile-phone services business to Bharti Airtel”

Timeline

Date	Event
Pre-2016	Tata Teleservices operates as one of India’s mid-tier telecom players. Tata Sons begins sustained capital infusions to fund losses and debt repayments.
Sep 2016	Reliance Jio launches — offering free voice calls and data. Analysts warn that the move makes survival of smaller telecom players ‘very difficult.’ Tata Teleservices’ losses accelerate.
Sep 2017	Tata Group announces sale of Tata Teleservices consumer mobile telephony business to Bharti Airtel in a no-cash deal. At this stage, analysts warn the exit alone could cost $4–5 billion.
2014 – 2019	Tata Sons infuses approximately ₹46,595 crore into Tata Teleservices to fund losses, debt repayments, and capital expenditure.
Jul 2019	Tata pays lenders and the government approximately ₹500 billion ($7.3 billion) to settle dues and complete the mobile business transfer. Consumer mobile business becomes part of Bharti Airtel on 1 July 2019.
FY2020	Tata Teleservices reports a net loss of ₹13,225 crore. Accumulated losses reach ₹48,907 crore.
Jan 2020	Supreme Court orders Tata Teleservices to pay ~₹13,823 crore in Adjusted Gross Revenue (AGR) dues to the government. Tata Sons arranges ₹10,000 crore from banks and the rest from internal accruals.

The Strategic and Exit Failure

The Tata Teleservices case is different from HP and Ranbaxy in one important respect: there was no external fraud and no hidden regulatory file. The problem was a series of ongoing strategic and investment decisions that did not adequately account for two risks that were, in hindsight, clearly building.

First, competitive disruption risk: Reliance Jio’s entry was not without precursor signals — the group had been preparing its launch for years. A rigorous strategic review of Tata Teleservices’ viability in a post-disruption market, and a realistic stress-test of exit costs, could and should have informed the decision to continue investing rather than exit earlier.

Second, regulatory liability: AGR dues — Adjusted Gross Revenue payments owed to the government — had been a disputed issue across the telecom sector for years before the Supreme Court’s 2019 ruling that crystallised the liability. A thorough assessment of contingent regulatory exposure would have mapped this risk well before the court forced it onto the balance sheet.

Case 2 – HP and Autonomy (2011): The $8.8 Billion Write-Off

The Deal

Autonomy Corporation was founded in Cambridge in June 1996 by Michael Lynch and Richard Gaunt as a spin-off from Cambridge Neurodynamic. By 2011 it had grown into one of Europe’s most prominent enterprise software companies, building products around big data analytics, information governance, and digital marketing, and was a constituent of the FTSE 100.

On 18 August 2011, HP announced it would acquire Autonomy at $42.11 per share — a 79% premium over market price. The move was immediately and widely criticised as excessive. HP’s own CFO reportedly disagreed with the price. Despite this, both boards approved the deal unanimously. It closed on 3 October 2011, with HP acquiring approximately 87.3% of shares for around $10.2 billion, valuing the company in total at approximately $11.7 billion.

What Went Wrong

In November 2012 — barely thirteen months after closing — HP announced an $8.8 billion accounting charge against Autonomy’s carrying value, alleging “serious accounting improprieties” and “outright misrepresentations” by Autonomy’s previous management. HP’s share price fell to a decades-low on the news. Mike Lynch, Autonomy’s co-founder, who had quietly departed as CEO in May 2012 after a significant revenue drop, denied the allegations entirely — attributing the problems to HP’s own mismanagement and what he called “internecine warfare” within the organisation.

What followed was one of the most protracted and complex legal disputes in corporate history. The UK Serious Fraud Office investigated and closed its inquiry in January 2015. Former Autonomy CFO Sushovan Hussain was found guilty of accounting fraud in the US in April 2018; his appeal failed in August 2020. HP brought a civil action in the UK courts in March 2019 — a trial lasting 93 days, with Lynch in the witness box for 22 days. In January 2022, the UK High Court ruled that HP had “substantially won” its civil case, finding that Lynch and Hussain had “artificially inflated Autonomy’s reported revenues, revenue growth and gross margins.”

The US criminal trial delivered a different verdict. Lynch and former VP of Finance Stephen Chamberlain faced trial in San Francisco in March 2024. On 6 June 2024, both were found not guilty on all charges. The case that had consumed more than a decade of litigation ended in acquittal.

In a separate but directly connected development, Deloitte — Autonomy’s auditor for 2009 to 2011 — was fined £15 million by UK regulators in September 2020 for what they described as “serious and serial failures” in its audits of the company during those years.

Compose rich HTML documents online without installing any software. A pro subscription gives you full access.

Timeline

Date	Event
Jun 1996	Autonomy Corporation founded in Cambridge, England by Michael Lynch and Richard Gaunt as a spin-off from Cambridge Neurodynamic.
2009	Analyst Paul Morland starts raising concerns about Autonomy’s exaggerated performance claims. HP’s own CFO later reported to have disagreed with the eventual acquisition price.
18 Aug 2011	HP announces acquisition at $42.11/share — a 79% premium over market price. Oracle’s Larry Ellison publicly calls the price ‘absurdly high.’
3 Oct 2011	Deal closes. HP acquires ~87.3% of shares for ~$10.2 billion, total valuation ~$11.7 billion.
May 2012	Mike Lynch exits as CEO of HP Autonomy after a significant revenue drop in the prior quarter.
Nov 2012	HP takes an $8.8 billion accounting charge, alleging ‘serious accounting improprieties’ and ‘outright misrepresentations.’ Lynch says problems are due to HP’s mismanagement.
Jan 2015	UK Serious Fraud Office closes its investigation — chance of successful prosecution assessed as low.
Apr 2018	Former Autonomy CFO Sushovan Hussain found guilty of accounting fraud in the US. His appeal later fails in August 2020.
Jan 2022	UK High Court rules HP had ‘substantially won’ its civil fraud case — Lynch and Hussain found to have artificially inflated revenues, growth, and margins.
Sep 2020	Deloitte — Autonomy’s auditor for 2009–2011 — fined £15 million by UK regulators for ‘serious and serial failures’ in its audits.
6 Jun 2024	US criminal trial: Lynch and Chamberlain found NOT GUILTY on all charges in San Francisco.

The Diligence Failure

The HP-Autonomy case is unusual because no single forum ever produced a definitive, unchallenged account of what actually happened. What is clear is this: HP paid a 79% premium for a software company whose revenue composition — specifically, what proportion came from recurring software licences versus one-time hardware sales — was the entire basis for the valuation. That revenue composition was not independently verified before the deal closed. Analyst concerns about Autonomy’s performance claims had been publicly raised since 2009. HP’s own CFO had reportedly disagreed with the price. Oracle’s CEO had called it absurdly high before the ink was dry. None of it stopped the deal. And the auditor whose work HP would have relied on for independent comfort was subsequently found, by UK regulators, to have committed serious and serial failures in that very work. In a deal of this size, independent forensic verification of revenue is not optional. It is the deal.

Case 3 – Daiichi Sankyo and Ranbaxy (2008–2016): Buying a Regulatory Time Bomb

The Deal

Ranbaxy Laboratories was incorporated in India in 1961 and had grown into one of the country’s largest generic pharmaceutical companies. By the mid-2000s, overseas markets accounted for 75% of its global sales, with the United States at 28%. For Daiichi Sankyo, a major Japanese pharmaceutical company, acquiring Ranbaxy was a bold entry into generic drugs and a platform into the US market.

In June 2008, Daiichi purchased a 34.8% stake from Ranbaxy’s CEO Malvinder Mohan Singh for ₹10,000 crore (approximately $2.4 billion) at ₹737 per share. By November 2008, Daiichi had spent an additional $2.2 billion to complete the takeover and become Ranbaxy’s majority shareholder. Total investment: approximately $4.6 billion.

What Was Already Known — Before the Deal Closed

This is what makes the Ranbaxy case so instructive. The regulatory problems weren’t discovered post-acquisition. They had been building and documented for years before Daiichi signed anything.

• In October 2003 – five years before the deal — Ranbaxy hired Lachman Consultant Services to audit the company. Lachman found that Ranbaxy’s Patient Safety Department did not seriously investigate patient reports of ineffectiveness or harmful side effects, and identified poor record-keeping in manufacturing plants.
• In October 2004, R&D Director Rajinder Kumar resigned after the Ranbaxy board refused to recall drugs he had shown were approved using fraudulent testing. Whistleblower Dinesh Thakur also resigned — after Ranbaxy reportedly tried to plant pornography on his computer to engineer a for-cause dismissal. Kumar and Thakur’s whistleblower report eventually reached the FDA.
• In September 2008 – the same weeks Daiichi was completing its takeover – the FDA issued an Import Alert for drugs from two Ranbaxy plants in India, citing serious manufacturing deficiencies. This was a public, documented regulatory action against the company Daiichi was in the process of buying.

The Fallout

In February 2009, the FDA halted all drug application reviews from Ranbaxy’s Paonta Sahib plant after finding it had frequently falsified data. Singh was fired in May 2009 over what was described as perceived indifference to quality control. Problems kept coming: in November 2012, Ranbaxy halted production and recalled 41 lots of atorvastatin (the generic version of Lipitor) after glass particles were found in bottles. In September 2013, further inspections found human hair in tablets, oil spots on other tablets, and toilet facilities without running water.

In May 2013, Ranbaxy pleaded guilty to seven felony counts — three violations of the Federal Food, Drug and Cosmetic Act and four counts of knowingly making false statements to the FDA — and agreed to pay $500 million in fines. It was the largest settlement ever by a generic drug company. Among the adulterated products were antiretroviral drugs intended for HIV/AIDS treatment in Africa.

In April 2014, Daiichi cut its losses – selling its 63.4% stake to Sun Pharmaceutical in a $4 billion all-stock deal, walking away from a $4.6 billion investment at a substantial loss. In 2016, the Singapore International Court of Arbitration ordered Ranbaxy’s former shareholders to pay Daiichi $525 million for intentionally misleading it about the severity of the regulatory scrutiny the company was facing at the time of the acquisition.

Timeline

Date	Event
Oct 2003	Lachman Consultant Services audits Ranbaxy and finds Patient Safety Department not investigating adverse reports, and identifies poor record-keeping in manufacturing plants.
Oct 2004	R&D Director Rajinder Kumar resigns after board refuses to recall fraudulently approved drugs. Whistleblower Dinesh Thakur also resigns. Their reports eventually reach the FDA.
Jun 2008	Daiichi Sankyo purchases 34.8% stake from CEO Malvinder Mohan Singh for ₹10,000 crore (~$2.4 billion) at ₹737/share.
Sep 2008	FDA issues Import Alert for drugs from two Ranbaxy plants — the same weeks Daiichi is completing its takeover — citing serious manufacturing deficiencies.
Nov 2008	Daiichi spends additional $2.2 billion to complete its majority takeover. Total investment: ~$4.6 billion.
Feb 2009	FDA halts all drug application reviews from Ranbaxy’s Paonta Sahib plant after finding systematic data falsification.
May 2009	Malvinder Singh fired as CEO over perceived indifference to quality control.
Nov 2012	Ranbaxy halts production and recalls 41 lots of atorvastatin (generic Lipitor) after glass particles found in bottles.
May 2013	Ranbaxy pleads guilty to 7 felony counts and pays $500 million in fines — the largest settlement ever by a generic drug company. Adulterated products included ARV drugs for HIV/AIDS treatment in Africa.
Apr 2014	Daiichi sells its entire 63.4% stake to Sun Pharmaceutical for $4 billion in an all-stock deal, exiting at a significant loss.
2016	Singapore International Court of Arbitration orders former Ranbaxy shareholders to pay Daiichi $525 million for intentionally misleading it on the severity of regulatory exposure.

The Diligence Failure

The 2003 Lachman audit, the 2004 R&D director’s resignation, and the September 2008 FDA Import Alert – the last of which was a public regulatory action issued in the very weeks Daiichi was completing its purchase – were all available before the deal closed. A thorough regulatory due diligence process, particularly in pharmaceuticals where FDA access is the core value driver, would have included direct engagement with regulatory records and independent assessment of manufacturing compliance. The 2016 Singapore arbitration finding – that Ranbaxy’s former shareholders had intentionally misled Daiichi about the severity of the regulatory position – confirms that the information existed. It just wasn’t surfaced.

Three Deals, Three Failures — At a Glance

Case	Total Spent	Core Failure	The Bill
HP / Autonomy (2011)	~$11.7 billion	Revenue composition not independently verified; auditor later fined £15M for serial audit failures	$8.8Bn written off within 13 months
Daiichi / Ranbaxy (2008–2016)	~$4.6 billion	Pre-existing FDA investigations and internal whistleblower alerts were available but not surfaced	$500M criminal fine + $525M arbitration + sold stake at a loss
Tata Teleservices (2017–2020)	₹46,595 crore infused (2014–2019)	Competitive risk (Jio’s entry) and regulatory liabilities (AGR dues) not adequately stress-tested in ongoing strategy decisions	$7.3Bn to settle exit dues + ₹13,823Cr AGR liability

The Blind Spots These Cases Exposed

The failures across these three cases cover very different industries and different types of oversight – but the underlying patterns rhyme closely:

Blind Spot	What It Actually Looked Like
Taking financials at face value	HP accepted Autonomy’s revenue mix without independently tracing it to signed contracts, bank deposits, or third-party confirmations. The revenue composition was the entire valuation argument — and it was never verified.
Ignoring regulatory exposure	Ranbaxy had an internal audit flagging problems (2003), an R&D director who resigned over fraudulent approvals (2004), and a public FDA Import Alert (Sep 2008) – all before Daiichi completed its takeover. A direct review of FDA inspection records would have surfaced the risk.
Overpaying on strategic logic	HP paid a 79% premium on the logic of transforming into a software company fast – a rationale HP’s own CFO reportedly disagreed with. Oracle’s Larry Ellison called the price absurdly high before the deal closed. Strategic urgency suppressed financial discipline.
Trusting the auditor too much	Deloitte audited Autonomy for 2009–2011 and was later fined £15M for ‘serious and serial failures.’ Relying on the target’s existing audit relationship – rather than commissioning an independent quality-of-earnings review – is a structural gap in any large deal.
Underestimating exit costs and regulatory liabilities	Tata continued to infuse ₹46,595 crore into Teleservices over six years without an exit plan that accounted for the full cost of leaving – including AGR dues that eventually crystallised as a ₹13,823 crore Supreme Court-mandated liability.
Missing competitive disruption risk	Tata’s ongoing investment decisions in telecom did not adequately price in the risk of a market-restructuring entrant like Jio. When Jio launched in 2016, analysts immediately warned that survival for smaller players was near-impossible – a risk that should have been stress-tested years earlier.

The Lessons That Keep Getting Ignored

• Verify revenue independently. Revenue composition is not a management narrative; it is a fact that must be independently tested and verified.
• Trace every material revenue line to signed contracts, bank statements, and third-party confirmations. Don’t accept management’s characterisation of their own income mix without checking it.
• Regulatory due diligence means going to the source. In regulated sectors -pharmaceuticals, telecom, financial services – go directly to the regulator’s records, not just the target’s own compliance narrative. Public FDA Import Alerts, inspection records, and AGR liability registers are available before you sign.
• Red flags are not yellow flags. When warning signs exist before the deal – an analyst raising concerns, a CFO’s internal objection, a whistleblower resignation, a public regulatory action – the question isn’t whether to proceed. It’s whether those signals have been rigorously investigated and priced into the deal structure.
• Your auditor’s auditor is not your auditor. The Deloitte fine in the HP – Autonomy case makes this explicit: the target’s own auditor is not your auditor. Independent quality-of-earnings work, separate from the existing audit relationship, is non-negotiable for any material acquisition.
• Know what it costs to leave before you decide to stay. Exit costs are as important to model as entry costs. Tata’s experience shows that continuing to invest in a deteriorating business without a stress-tested exit plan can result in a settlement bill that dwarfs the original investment thesis.

Conclusion — The Most Expensive Questions Are the Ones Never Asked

HP didn’t know it was buying an $8.8 billion write-off. Daiichi didn’t know it was buying a company already under FDA investigation. Tata didn’t model what a full exit from telecom would actually cost when competitive and regulatory conditions turned against it. Or more precisely, in each case, the critical risks were either not independently verified, not fully surfaced, or not adequately incorporated into the decision before it was too late to change course. Due diligence, whether before an acquisition or before a major ongoing investment decision, is not a formality. It is the only moment where an independent mind can ask the question the deal team doesn’t want to ask: what if this isn’t what it looks like? In all three of these cases, that question went either unasked, unanswered, or unheeded. The price was measured in billions.

By,

Team AnBac Advisors

Disclaimer: The intent of this article is knowledge sharing with facts for increasing awareness on tax and corporate matters, and no intention exits to discuss or share opinion on any specific company or its operations.